| Corporate Presentation (August 2021) Pipeline and products: Gene Therapies The following report will aim to present a comprehensive overview of where Rocket Pharmaceuticals is today and the potential/risks upcoming in the 4Q 2021 data announcement. If successful, Rocket Pharmaceuticals could revolutionize the gene therapy market yet again, but the sizeable upside comes with sizeable risk. The therapeutic programs underway have already shown promising curative potential, but have increased investor concerns with the safety of Rocket's gene therapies and the FDA's willingness to accept such risk levels. Wall Street has an overwhelmingly bullish sentiment by all 12 following Wall Street analysts with the only debate being on how quickly Rocket can complete their fast-tracked clinical trials. The potential of Rocket Pharma is one of the highest this author has seen. The current platform is using ex-vivo lentiviral vectors and in-vivo adeno-associated virus vectors showcasing impressive early efficacy data for the associated target genes driving strong wall-street optimism.įounded in 1999, Rocket Pharma has grown to 91 employees and a market cap of $2.12B (Sep. ( NASDAQ: RCKT) is a clinical-stage, multi-platform biotechnology company developing gene therapies with a focus on direct on-target mechanisms of action for rare and devastating orphan diseases.
Introduction: What is Rocket Pharmaceuticals? Graphic Source: Rocket Pharmaceuticals, Inc.
0 kommentar(er)
